Randomized Double-blind, Placebo-controlled, Multicenter Clinical Study of Nimotuzumab Combined With Trifluridine/Tipiracil in Third-line and Beyond for the Treatment of Metastatic Colorectal Cancer
Latest Information Update: 04 Apr 2024
At a glance
- Drugs Nimotuzumab (Primary) ; Tipiracil/trifluridine
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NOTABLE-308
- Sponsors Biotech Pharmaceutical
Most Recent Events
- 04 Apr 2024 New trial record